# Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…

> PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30206903-lixisenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30206903-lixisenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30206903-lixisenatide-v1.json
- Content SHA-256: `0595dcd2cfc69b41636fa9988cf543c540ec4d863c6eb2bd06495ee7d62d7f0b`

## Claims and source pins

### Headline

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice… ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

### Summary

PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

### Paragraph 1

PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`](#source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1))

## Sources

<a id="source-pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1"></a>
- **Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study. · retained source version 1:2023-05-22:current:502cc3c3cdd1b02975408a6a37541b69f2c1124087ecd4220c5cf269bfa55ebb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30206903/) (`pubmed-observation-pmid-30206903-2023-05-22-502cc3c3cdd1`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30206903-lixisenatide-v1.json SHA-256: 0595dcd2cfc69b41636fa9988cf543c540ec4d863c6eb2bd06495ee7d62d7f0b.